title: Preliminary estimation of treatment effect on uterine cervical squamous cell carcinoma in terms of tumor regression rate: comparison between chemoradiotherapy and radiotherapy alone.
abstract: OBJECTIVE
  We preliminarily estimated the treatment effect on cervical cancer in terms of the tumor regression rate (TRR) achieved with chemoradiotherapy and radiotherapy alone.
  
  
  METHODS
  The study included cervical squamous cell carcinomas treated by radiotherapy alone (n=45) or chemoradiotherapy (concurrent once-a-week cisplatin 30 mg/m2, n=13). Tumors were measured three-dimensionally on pre- and mid-treatment magnetic resonance images. TRR was defined as the slope of the exponential regression curve of tumor volume (day(-1)) on the assumption that tumors regressed exponentially with time.
  
  
  RESULTS
  TRR ranged widely (0.004-0.090 day-(-1)) and did not significantly differ between treatment with chemoradiotherapy (median, 0.032 day(-1)) and with radiotherapy alone (median, 0.024 day(-1)) (p = 0.361). TRR > 0.05 day(-1) was seen in four chemoradiotherapy tumors (30.8%) and in six radiotherapy-alone tumors (15.0%) (p = 0.207), whereas TRR < 0.01 day(-1) was seen in no chemoradiotherapy tumors (0.0%) and in five radiotherapy-alone tumors (11.1%) (p = 0.180). TRR for tumors > 5.0 cm in diameter was greater with chemoradiotherapy (n=5) than with radiotherapy alone (n=12) (p = 0.065).
  
  
  CONCLUSIONS
  Although the difference did not reach a statistically significant level, our TRR data suggest that concurrent chemotherapy heightens the radioresponse of large-size cervical cancer.
authors.affiliation: Department of Radiation Oncology, Tsukuba University Hospital, University of Tsukuba, Japan.
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ohara
authors.forename: Yumiko Oishi
authors.initials: YO
authors.lastname: Tanaka
authors.forename: Hajime
authors.initials: H
authors.lastname: Tsunoda
authors.forename: Akinori
authors.initials: A
authors.lastname: Oki
authors.forename: Toyomi
authors.initials: T
authors.lastname: Satoh
authors.forename: Kayoko
authors.initials: K
authors.lastname: Onishi
authors.forename: Kenji
authors.initials: K
authors.lastname: Kagei
authors.forename: Shinji
authors.initials: S
authors.lastname: Sugahara
authors.forename: Masaharu
authors.initials: M
authors.lastname: Hata
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Igaki
authors.forename: Koichi
authors.initials: K
authors.lastname: Tokuuye
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Akine
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yoshikawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D016009:Chi-Square Distribution; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D012044:Regression Analysis; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin